Table 3.
Genotype and allelic frequencies of TNF-α (− 308G/A, + 488G/A, − 857C/T and -1031 T/C) gene polymorphisms in IS patients and controls.
| Polymorphisms | LVD N = 107 |
SVD N = 83 |
CE N = 26 |
Others N = 34 |
IS N = 250 |
Controls N = 250 |
||
|---|---|---|---|---|---|---|---|---|
| G308A | Genotype | GG, n (%) | 93 (86.9) | 75 (90.3) | 23 (88.5) | 27 (79.4) | 218 (86.8) | 225 (90) |
| GA, n (%) | 14 (13) | 7 (8.4) | 3 (11.5) | 5 (14.7) | 29 (11.6) | 23 (9.2) | ||
| AA, n (%) | 0 | 1 (1.2) | 0 | 2 (5.8) | 3 (1.2) | 2 (0.8) | ||
| Allele | G, n (%) | 200 (93.4) | 157 (94.5) | 49 (94.2) | 59 (86.7) | 465 (93) | 473 (94.6) | |
| A, n(%) | 14 (6.6) | 9 (5.5) | 3 (5.8) | 9 (13.2) | 35 (7) | 27 (5.4) | ||
| Dominant GA + GG vs. AA | Adjusted OR (95% CI), P value | 1.40 (0.59–3.35), 0.43 | 1.04 (0.37–2.88), 0.93 | 1.59 (0.35–7.29), 0.54 | 4.57 (1.39–15.0), 0.01 | 1.42 (0.73–2.76), 0.3 | ||
| Unadjusted OR (95% CI), P value | 1.35 (0.67–2.72), 0.39 | 0.96 (0.41–2.21), 0.92 | 1.17 (0.32–4.18), 0.80 | 2.33 (0.92–5.90), 0.07 | 1.36 (0.75–2.47), 0.29 | |||
| Recessive AA vs. GA + GG | Adjusted OR (95% CI), P value | NE | 4.94 (0.41–58.79), 0.20 | NE | NE | 4.15 (0.63–27.30), 0.13 | ||
| Unadjusted OR (95% CI), P value | NE | 1.51 (0.13–16.89), 0.73 | NE | 1.75 (1.05–56.93), 0.04 | 1.49 (0.25–8.97), 0.65 | |||
| Allelic A vs. G | OR (95% CI), P value | 1.22 (0.62–2.38), 0.54 | 1.00(0.46–2.18), 0.56 | 1.07 (0.31–3.66), 0.55 | 2.67(1.19–5.95), 0.01 | 1.31 (0.78–2.21) ,0.29 |
||
| Polymorphisms | LVD N = 107 |
SVD N = 83 |
CE N = 26 |
Others N = 34 |
IS N = 250 |
Controls N = 250 |
||
|---|---|---|---|---|---|---|---|---|
| G488A | Genotype | GG, n (%) | 68 (63.5) | 59 (71) | 18 (69.2) | 17 (50) | 162 (64.8) | 192 (76.8) |
| GA, n (%) | 36 (33.6) | 22 (26.5) | 8 (30.8) | 16 (47) | 82 (32.8) | 55 (22) | ||
| AA, n (%) | 3 (2.8) | 2 (2.4) | 0 | 1 (3) | 6 (2.4) | 3 (1.2) | ||
| Allele | G (%) | 172 (80.4) | 140 (84.3) | 44 (84.6) | 50 (73.5) | 406 (81.2) | 439 (87.7) | |
| A (%) | 42 (19.6) | 26 (15.7) | 8 (15.4) | 18 (26.4) | 94 (18.8) | 61 (12.2) | ||
| Dominant (GG + GA vs. AA) | Adjusted OR (95% CI), P value | 2.23 (1.20–4.14), 0.01 | 2.33 (1.17–4.65), 0.01 | 1.89 (0.65–5.50), 0.23 | 4.88 (1.90–12.52), 0.01 | 2.59 (1.46–4.60), 0.001 | ||
| Unadjusted OR (95% CI), P value | 1.89 (1.16–3.10), 0.01 | 1.34 (0.77–2.35), 0.29 | 1.47 (0.60–3.55), 0.39 | 3.31 (1.58–6.89), 0.001 | 1.78 (1.20–2.66), 0.004 | |||
| Recessive (GG vs. AA + GA) | Adjusted OR (95% CI), P value | 2.12 (0.22–19.93), 0.50 | 1.61 (0.14–18.29), 0.70 | NE | 0.58 (0.03–10.91), 0.72 | 1.75 (0.29–10.33), 0.53 | ||
| Unadjusted OR (95% CI), P value | 2.37 (0.47–11.96), 0.29 | 2.03 (0.33–12.380, 0.44 | NE | 2.49 (0.25–24.69), 0.43 | 2.00 (0.50–7.99), 0.32 | |||
| Allelic G vs. A | OR (95% CI), P value | 1.75 (1.14–2.70), 0.009 | 1.33 (0.81–2.19), 0.25 | 1.30 (0.58–2.91), 0.50 | 2.59 (1.41–4.72), < 0.001 | 1.66 (1.17–2.36), 0.003 |
||
| Polymorphisms | LVD N = 107 |
SVD N = 83 |
CE N = 26 |
Others N = 34 |
IS N = 250 |
Controls N = 250 |
||
|---|---|---|---|---|---|---|---|---|
| C857T | Genotype | CC, n (%) | 71 (66.3) | 59 (71) | 18 (69.2) | 22 (64.7) | 170 (68) | 172 (68.8) |
| CT, n (%) | 29 (27.1) | 21 (25.3) | 7 (26.9) | 10 (29.4) | 67 (26.8) | 68 (27.2) | ||
| TT, n (%) | 7 (6.5) | 3 (3.6) | 1 (3.8) | 2 (5.8) | 13 (5.2) | 10 (4) | ||
| Allele | C (%) | 171 (79.9) | 139 (83.7) | 43 (82.6) | 54 (79.4) | 407 (81.4) | 412 (82.4) | |
| T (%) | 43 (20.1) | 27 (16.3) | 9 (17.4) | 14 (20.5) | 93 (18.6) | 88 (17.6) | ||
| Dominant CC + CT vs. TT | Adjusted OR (95% CI), P value | 1.57 90.86–2.86), 0.13 | 1.74 (90.89–3.36), 0.10 | 1.51 (0.53–4.29), 0.43 | 1.52 (0.61–3.82), 0.36 | 1.77 (1.01–3.11), 0.04 | ||
| Unadjusted OR (95% CI), P value | 1.11 (0.69–1.81), 0.65 | 0.89 (0.52–1.54), 0.69 | 0.98 (0.40–2.35), 0.l9 | 1.20 (0.56–2.55), 0.63 | 1.03 (0.71–1.51), 0.84 | |||
| Recessive TT vs. CT + CC | Adjusted OR (95% CI), P value | 2.32 (0.69–7.73), 0.17 | 1.17 (0.25–5.28), 0.83 | 0.76 (0.07–8.01), 0.82 | 3.14 (0.53–18.47), 0.20 | 1.70 (0.62–4.60), 0.29 | ||
| Unadjusted OR (95% CI), P value | 1.68 (0.62–4.53), 0.30 | 0.90 (0.24–3.35), 0.87 | 0.96 (0.11–7.81), 0.11 | 1.50 (0.31–7.15), 0.61 | 1.33 (0.56–3.16), 0.51 | |||
| Allelic T vs. C | OR (95% CI), P value | 1.17 (0.78–1.76), 0.43 | 0.90 (0.56–1.45), 0.68 | 0.97 (0.46–2.08), 0.56 | 1.21 (0.64–2.28), 0.54 | 1.06 (0.77–1.47), 0.68 |
||
| Polymorphisms | LVD N = 107 |
SVD N = 83 |
CE N = 26 |
Others N = 34 |
IS N = 250 |
Controls N = 250 |
||
|---|---|---|---|---|---|---|---|---|
| T1031C | Genotype | TT, n (%) | 64 (59.8) | 39 (46.9) | 13 (50) | 18 (52.9) | 134 (53.6) | 121 (48.4) |
| TC, n (%) | 34 (31.7) | 26 (31.3) | 12 (46.1) | 13 (38.2) | 35 (38) | 115 (46) | ||
| CC, n (%) | 9 (8.4) | 8 (9.6) | 1 (3.8) | 3 (8.8) | 21 (8.4) | 14 (5.6) | ||
| Allele | T (%) | 162 (75.7) | 114 (68.6) | 38 (73) | 49 (72) | 363 (72.6) | 357 (71.4) | |
| C (%) | 52 (24.2) | 52 (31.3) | 14 (27) | 19 (28) | 137 (27.4) | 143 (28.6) | ||
| Dominant (TT + TC vs. CC) | Adjusted OR (95% CI), P value | 0.54 (0.31–0.96), 0.03 | 1.09 (0.60–1.99), 0.76 | 0.96 (0.36–2.54), 0.94 | 0.83 (0.35–1.97), 0.67 | 0.54 (0.31–0.91), 0.02 | ||
| Unadjusted OR (95% CI), P value | 0.63 (0.39–0.99), 0.04 | 1.05 (0.64–1.74), 0.82 | 0.93 (0.41–2.10), 0.87 | 0.83 (0.40–1.70), 0.62 | 0.81 (0.57–1.15), 0.25 | |||
| Recessive CC vs. TC + TT | Adjusted OR (95% CI), P value | 1.94 (0.69–5.45), 0.20 | 2.46 (0.84–7.16), 0.09 | 0.66 (0.05–8.53), 0.75 | 2.31 (0.48–11.10), 0.29 | 1.60 (0.70–3.64), 0.26 | ||
| Unadjusted OR (95% CI), P value | 1.54 (0.64–3.69), 0.32 | 1.79 (0.72–4.45), 0.20 | 0.67 (0.08–5.34), 0.70 | 1.63 (0.44–5.99) 0.46 | 1.50 (0.76–2.94), 0.24 | |||
| Allelic C vs. T | OR (95% CI), P value | 0.80 (0.55–1.15), 0.23 | 1.13 (0.77–1.60), 0.56 | 0.91 (0.48–1.74), 0.79 | 0.96 (0.55–1.70), 0.92 | 0.94 (0.71–1.24), 0.67 | ||
Abbreviations: LVD- large vessel stroke; SVD-small vessel stroke; CE-cardioembolic stroke; others includes- stroke due to undetermined aetiology + other determined aetiology; IS-Ischemic Stroke; NE- Not Estimable; OR- Odds Ratio; CI- Confidence Interval.